Short-chain fatty acids (SCFAs) are fermentation end products produced by the intestinal
microbiota and have anti-inflammatory and histone deacetylase–inhibiting properties.
Recently, a dual relationship between the intestine and kidneys has been unraveled.
Therefore, we evaluated the role of SCFA in an AKI model in which the inflammatory process
has a detrimental role. We observed that therapy with the three main SCFAs (acetate,
propionate, and butyrate) improved renal dysfunction caused by injury. This protection was …